Osteonecrosis of the jaw and bisphosphonates: A comparison with white phosphorus, radium, and osteopetrosis

Clinical Toxicology

Volumn 45, Issue 7, 2007, Pages 753-762

  Vance, Michael A ^a  

^a BUTLER UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Jaw necrosis; Osteopetrosis; Phosphorus; Radium; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINOBISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PHOSPHORUS; RADIUM; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; BONE NECROSIS; BREAST CANCER; DRUG SUBSTITUTION; HUMAN; JAW NECROSIS; MEDICAL RESEARCH; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; SKELETON MALFORMATION; SOCIAL ASPECT;

ANIMALS; BONE RESORPTION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOGS; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPETROSIS; PHOSPHORUS; RADIATION INJURIES; RADIUM;

EID: 36749082920     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701232505     Document Type: Review

References (133)

1. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Eng J Med 1998; 339:947-952.
2. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003; 14:617-630.
3. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clinical Oncology 2003; 21:4253-4254.
4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced asvascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-1117.
5. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575.
6. Bamais A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphophonates: incidence and risk factors. J Clin Oncol 2005; 23:8580-8587
7. Lai K-A, Shen W-J, Yang C-Y, Shao C-J, Hsu J-T, Lin R-M. The use of alendronate to prevent early collapse of the femoral head in patients with nontruamatic osteonecrosis. J Bone Joint Surg 2005; 87A:2155-2159.
8. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaw associated with cancer chemotherapy. J Oral Maxillfac Surg 2003; 61:1104-1107.
9. Tarassoff P, Csermak, K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J Oral Maxillfac Surg 2003; 61:1238-1239.
10. th element: The sordid tale of murder, fire and phosphorus. New York: John Wiley & Sons Inc., 2000.
11. Gordon B. Phossy jaw and the French match makers: Occupational health and women in the Third Republic. New York: Garland Publishing Inc., 1989.
12. Schirmer I, Peters H, Reichart R, Durkop H. Bisphoshonate und Oseonekrosen im Kieferbereich. Mund Kifer Gesichts Chir 2005; 9:239-245.
13. Schwartz H. Osteonecrosis and bisphosphonates: Correlation versus causation. J Oral Maxillofac Surg 2004; 62:763-764.
14. Young D. ONJ reported in bisphosphonate-treated patients. In: Oncologic Drugs Advisory Committee, volume II, Food and Drug Administration Center for Drug Evaluation and Research hearings, March 4, 2005:231-237. Accessed October 31, 2005, at http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4095T2.htm
15. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation by caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacologic classes of bisphosphonate drugs. Mol Pharmacol 1999; 56:131-140.
16. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon MP, Benford HL, Croucher PI, Shipman C, Fleisch HA. The pharmacology of bisphosphonates and new insights into their mechanisms of actions. J Bone Miner Res 1999; 14(Suppl 2):53-65.
17. MacGowan JR, Pringle J, Morris VH, Stamp TC. Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. Skeletal Radiol 2000; 29:279-282.
18. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate. Arthritis Rheum 2001; 44:2201-2210.
19. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reska AA. Alendronate mechanism of action: geranylgeraniol, an intermendiate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Nat Acad Sci 1999; 96:133-138.
20. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373:231-241.
21. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004; 4:711-719.
22. Widler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, Klein R, Ramseier U, Schmid J, Schreiber G, Seltenmeyer Y, Green JR. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002; 45:3721-3738.
23. Sato M, Grasser W, Endo N, Atkins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095-2105.
24. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: Differences in interaction with hydroxyapatite. Bone 2006; 38:617-627.
25. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18:75-85.
26. Cremers SCLM, Goonaseelan P, Papapoulos SE. Pharmacokinetics/ pharmacodynamics of bisphosphonates: Use for optimization of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44:551-570.
27. Favus MJ, Vokes TJ. Paget disease and other dysplasias of bone. In: Kasper DL, Fauchi AS, Braunwald E, Hauser S, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine, 16th ed. New York: McGraw-Hill, 2005:2279-2282.
28. Van der Pluijm G, Vloedgraven H, van Beek E, van der WeePals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98:698-705.
29. Green JR. Bisphosphonates: Preclinical review. Oncologist 2004; 9(Suppl 4):3-13.
30. Felton JS. Phosphorus necrosis - A classical occupational disease. Am J Industrial Medicine 1982; 3:77-120.
31. Myers ML, McGlothlin JD. Matchmakers' "phossy jaw" eradicated. Am Ind Hyg Assoc J 1996; 57:330-332.
32. Anonymous. The manufacture of Lucifer matches. Manufacturer and Builder Sept. 1869, Vol. 1 (#9):268-269. Accessed September 6, 2005, at http://cdl.library.cornell.edu/cgi-bin/moa/pageviewer?root= %2Fmoa%2Fmanu%2Fmanu0001%2F&tif=00274.TIF&cite=http%3A%2F%2Fcdl.library. cornell.edu%2Fcgi-bin%2Fmoa%2Fmoa-cgi%3Fnotisid%3DABS1821-0001-523&coll= moa&frames=1&view=50
33. Heimann H. Chronic phosphorus poisoning. J Indust Hyg Toxicol 1946; 28:142-150.
34. Hamilton A. Chronic phosphorus poisoning. In: Kober G, Hanson WK, eds. Diseases of occupation and industrial hygiene. Philadelphia: P. Blackstones & Sons & Co., 1916:145-152.
35. Henderson Y, Haggard HW. Noxious gases and the priciples of respiration influencing their action. American Chemical Society Monograph Series No. 25. New York: The Chemical Catalog Company, 1927:182-184.
36. Hamilton A. Exploring the dangerous trades. Boston: Little, Brown & Co., 1943.
37. Boyd LJ. Phosphorus. The Hahnemannian Monthly 1924; 59:129-138.
38. Wakefield BG. Phosphorous necrosis of the mandible: report of two cases. J Oral Surg 1948; 6:263-268.
39. Adams CO, Sarnat B. Effects of yellow phosphorus and arsenic trioxide on growing bones and growing teeth. Arch Pathology 1940; 30: 1192-1202.
40. Fleming RBL, Miller JW, Swayne Jr VR. Some recent observations on phosphorus toxicology. J Indust Hygeine 1942; 24:154-158.
41. Wegner G. Der Einfluss des Phosphors auf den Organismus. Virchows Arch f. path Anat 1872; 55:11-45.
42. Hughes JPW, Baron R, Buckland DH, Cooke MA, Craig JD, Duffield DF, Grosart AW, Parker PW, Porter A. Phosphorus necrosis of the jaw: a present-day study. Brit J Industr Med 1962; 19:83-99.
43. Agency for Toxic Substance and Disease Registry. Toxicological profile for white phosphorus, US Department of Health and Human Services, September 1997. Accessed October 30, 2005, at http://www.atsdr.cdc.gov/toxprofiles/tp103. pdf
44. Stewart E. Radium poisoning: Industrial poisoning from radioactive substances. Monthly Labor Rev 1929(June); 28:20-61.
45. St George AV, Gettler AO, Muller RH. Radioactive substances in a body five years after death. Arch Pathol 1929; 7:397-405.
46. Martland HS, Conlon P, Knef JP. Some unrecognized dangers in the use and handling of radioactive substances. J Amer Med Assoc 1925; 85:1769-1776.
47. Sharpe WD. The New Jersey radium dial painters: A classic in occupational carcinogenesis. Bull Hist Med 1979; 52:560-570.
48. Cloutier RJ. Florence Kelley and the radium dial painters. Health Physics 1980; 39:711-716.
49. Aub JC, Evans RD, Hempelmann LH, Martland HS. The late effects of internally-deposited radioactive materials in man. Medicine 1952; 31:221-329.
50. RE Marx. Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41:283-288.
51. Committee on the Biological Effects of Ionizing Radiations. Health risks of radon and other internally deposited alpha-emitters: BIER IV. Wahsington, DC: National Research Council, 1988.
52. Lacassagne A. Un nouvel accident professionnel des manipulateurs de corps radioactifs: la necrose des maxillaries. Paris Medical 1926; 16:132-135.
53. Gettler AO, Norrris C. Poisoning from drinking radium water. J Amer Med Assoc 1933; 100:400-402.
54. Macklis RM. The great radium scandal. Scientific American 1993; August:94-99.
55. Spiess H. Peteosthor - a medical disaster due to radium-224. Radiat Envion Biophys 2002; 41:163-172.
56. Lloyd RD, Taylor GN, Miller SC, Bruenger FW, Jee WSS. Review of 239Pu and 226Ra effects in beagles. Health Phys 2001; 81:691-697.
57. 224Ra-induced osteopenia in male CBA mice. Calcif Tissue Int 2000; 46:94-100.
58. Whyte MP. Osteopetrosis. In: Royce RM, Steinmann B, eds. Connective tissue and its heritable disorders, 2nd ed. New York: Wiley-Liss, 2002:789-807.
59. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. New Eng J Med 2004; 351:2839-2849.
60. Benichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albners-Schonberg disease): Clinical and radiological manifestations in 42 patients. Bone 2000; 26:87-93.
61. El-Tawil T, Stoker DJ. Benign osteopetrosis: A review of 42 cases showing two different patterns. Skeletal Radiol 1993; 22:587-593.
62. Kaczmarczyk-Sedlak I. The effect of pamidronate on mechanical properties, growth and structural changes in rat bones. Acta Poloniae Pharmaceutica 1995; 52:509-513.
63. Reynolds JJ, Murphy H, Muhlbauer RC, Fleisch H. Inhibition by diphosphonates in mice and comparison with gray-lethal osteopetrosis. Calcif Tiss Res 1973; 12:59-71.
64. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. New Eng J Med 2003; 349:457-463.
65. Steiner, Gould AR, Means WR. Osteomyelitis of the mandible associated with osteopetrosis. J Oral Maxillofac Surg 1963; 41:395-405.
66. Crockett DM, Stanley RB, Lubka R. Osteomyelitis of the maxilla in a patient with osteopetrosis (Albers-Schonberg disease). Otolaryngology-Head Neck Surg 1986; 95:117-121.
67. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273:1236-1238.
68. Gelb BD, Brömme D, Desnick RJ. Pycnodysostosis: Cathepsin K deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The metabolic and molecular basis of inherited disease, 8th ed. New York: McGraw-Hill, 2001:3453-3468.
69. Bouquot JE, McMahon RE. Neuropathic pain in maxillofacial osteonecrosis. J Oral Maxillofac Surg 2000; 58:1003-1020.
70. Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 2006; 73:7-9.
71. Kennon R, Hallam JW. Modern phophorus caries and necrosis. Br Dental 1944; 76:321-330.
72. Ward EF. Phosphorus necrosis in the manufacture of fireworks. J Indust Hyg 1928; 10:314-350.
73. Dearden WF. Fragilitas ossium amongst workers in Lucifer match factories. Brit Med J 1899; 2:270-271.
74. Stebbings JH. Health risks from radium in workplaces: An unfinished story. Occupational Medicine 2001; 16:259-270.
75. Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Rev 1998; 47:237-240.
76. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-1061.
77. Whalen JP, O'Donohue N, Krook L, Nunez EA. Pathogenesis of abnormal remodeling of bones: Effects of yellow phosphorus in the growing bone. Anat Rec 1973; 177:15-22.
78. Jee WSS, Bartley MH, Dockum NL, Yee J, Kenner GH. Vascular changes in bones following bone-seeking radionuclides. In: Mays CW, Jee WSS, Lloyd RD, eds. Delayed effects of bone-seeking radionuclides. Salt Lake City, UT: University of Utah Press, 1969.
79. Doty SB, Yates CW, Lotz WE, Kisecleski W, Talmage RV. Effect of short term alpha irradiation on parathyroid activity and osteoclast numbers. Proc Soc Exp Biol Med 1965; 119:77-81.
80. Scheven BAA, Burger EH, Kawilarang-de Haas EWM, Wassenaar AM, Nijweide PJ. Effects of ionizing irradiation on formation and resorbing activity of osteoclasts in vitro. Lab Invest 1985; 53:72-79.
81. Devogelaer J-P. Treatment of bone diseases with bisphosphonates. Curr Opinion Rheumatology 2000; 12:331-335.
82. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10:52-62.
83. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993; 53:283-288.
84. Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003; 32:45-55.
85. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 2003; 32:120-126.
86. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of ?1.6 to ?2.5 at the femoral neck: The Fracture Intervention Trial. Mayo Clin Proc 2005; 80:343-349.
87. Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrin Metab 1994; 78:968-972.
88. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: A histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000; 15:754-762.
89. Lenz J-H, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KKH. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J CranioMaxillofac Surg 2005; 33:395-403.
90. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of iv bisposphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10:842-848.
91. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. New Eng J Med 2005; 353:99-100.
92. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163:185-194.
93. Abu-Id MH, Acil Y, Gottschalk J, Kreusch T. Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund-, Kiefer- und Gesichtschir, 2006; 10:73-81.
94. A Lipton, RL Theriault, GN Hortobagyi, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88:1082-1090.
95. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen B-L, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003; 98:1735-1744.
96. Body J-J, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff WW, Gorbunova VA, Budde M, Bergstrom B. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14:1399-1405.
97. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlick M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other sold tumors: A phase III, double-blind, randomized trial - The Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003; 21:3150-3157.
98. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314-3321.
99. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal Intervention Cohort Study. A randomized, controlled trial. Ann Int Med 1999; 131:935-942.
100. McClung MR, Guesens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New Eng J Med 2001; 344:333-340.
101. Glueck CJ, McMahon RE, Bouquot J, Stroop D, Tracy T, Wang P, Rabinovich B. Thrombofilia, hypofibrinolysis, and alveolar osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Radiol Endod 1996; 81:557-566.
102. McMahon RE, Bouquot JE, Glueck CJ, Spolnik KJ, Adams WR. Osteonecrosis: A multifactorial etiology. J Oral Maxillofac Surg 2004; 62:904-905.
103. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90:1897-1899.
104. Whyte MP. The long and short of bone therapy. New Eng J Med 2006; 354:860-863.
105. Kaczmarczyk-Sedlak I. The effect of pamidronate on mechanical properties, growth and structural changes in rat bones. Acta Poloniae Pharmaceutica 1995; 52:509-513.
106. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:621-625.
107. Odvina CV. Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
108. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61:31-33.
109. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004; 19:1779-1786.
110. Lin JH, Chen I-W, Duggan DE. Effects of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Disp 1992; 20:473-478.
111. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer J-P, Kaufman J-M, Jaeger P, Body J-J, Mieunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New Eng J Med 2002; 346:653-661.
112. Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane Review). In: The Cochrane Library, 2005, Issue 2. Accession Number: CD003474.
113. Lugassy G. Safety and convenience of a 15-minute infusion of zoledronic acid: Not so safe. Oncologist 2005; 10:309-310.
114. Parles K. Regarding Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10:304-305.
115. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA 2004; 292:2647-2650.
116. Gibbs SDJ, O'Grady J, Seymour JF, Prince HM. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Australia 2005; 21:549-550.
117. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006; 81:73-75.
118. Najm SA, Lysitsa S, Carrel J-P, Lesclous P, Lombardi T, Samson. Osteonecrose des maxillaires chez des patients traites par bisphosphonates. Presse Med 2005; 34:1073-1077.
119. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphophonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc 2005; 136:1675-1681.
120. Farrugia M, Summerlin D-J, Krowiak, E, Huntley T, Freeman S, Borrowdale, R, Tomich C. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116:115-120.
121. Carter G, Goss ANN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Australia 2005; 182:413-415.
122. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. New Eng J Med 2005; 353:100-101.
123. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bishosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
124. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Oral Oncology 2006; 42:327-329.
125. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Australia 2005; 182:417-418.
126. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104:83-93.
127. Mullner R. Deadly glow: The radium dial worker tragedy. Washington DC: American Public Health Association, 1999.
128. Rowland RE. Radium in humans: a review of US studies. Argonne, Illinois: Argonne National Laboratory, 1994.
129. Clark C. Radium girls: Women and industrial health reform, 1910-1935. Chapel Hill: University of North Carolina Press, 1997.
130. Agency for Toxic Substance and Disease Registry: Toxicological profile for radium, US Department of Health and Human Services, December 1990. http://www.atsdr.cdc.gov/toxprofiles/tp144.pdf. Accessed 30 October 2005.
131. Castle WB, Drinker KR, Drinker CK. Necrosis of the jaw in workers employed in applying a luminous paint containing radium. J Indust Hyg 1925; 7:371-382.
132. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporosis Int 1998; 8:97-103.
133. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Nat Cancer Int 2004; 96:879-882.